Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
E-BookPDF1 - PDF WatermarkE-Book
188 Seiten
Englisch
Springer Londonerschienen am02.03.20092009
This book addresses the contemporary multidisciplinary management of liver metastases. Throughout the text, experience from the paradigms of colorectal cancer metastases treatment strategies are used to point to new directions in the management of liver metastases from other cancers.



The book will be invaluable for surgeons in general surgery, hepatobiliary surgery, upper GI surgery, colorectal surgery, medical and clinical oncologists with an interest in liver tumours, and radiologists with an interest in liver disease.mehr
Verfügbare Formate
BuchGebunden
EUR160,49
E-BookPDF1 - PDF WatermarkE-Book
EUR106,99

Produkt

KlappentextThis book addresses the contemporary multidisciplinary management of liver metastases. Throughout the text, experience from the paradigms of colorectal cancer metastases treatment strategies are used to point to new directions in the management of liver metastases from other cancers.



The book will be invaluable for surgeons in general surgery, hepatobiliary surgery, upper GI surgery, colorectal surgery, medical and clinical oncologists with an interest in liver tumours, and radiologists with an interest in liver disease.
Details
Weitere ISBN/GTIN9781846289477
ProduktartE-Book
EinbandartE-Book
FormatPDF
Format Hinweis1 - PDF Watermark
FormatE107
Erscheinungsjahr2009
Erscheinungsdatum02.03.2009
Auflage2009
Seiten188 Seiten
SpracheEnglisch
IllustrationenXII, 188 p.
Artikel-Nr.1011917
Rubriken
Genre9200

Inhalt/Kritik

Inhaltsverzeichnis
1;Liver Metastases;2
2;Preface;5
3;Contents;6
4;Contributors;8
5;Radiological Imaging of Liver Metastases;11
5.1;Introduction;11
5.2;Diagnosis and Staging of Liver Metastasis;11
5.3;Radiologic-Pathologic Correlation;12
5.4;Imaging Modalities for the Detection of Hepatic Metastases;13
5.4.1;Ultrasound;14
5.4.2;Computed Tomography;14
5.4.3;Magnetic Resonance Imaging;14
5.5;Differential Diagnosis;16
5.5.1;Hemangioma;16
5.5.2;Focal Steatosis;16
5.5.3;Sub-Centimeter Focal Lesions;16
5.6;Staging of Hepatic Metastases in Potentially Resectable Patients;17
5.6.1;Evaluation of Possible Liver Metastases;17
5.6.2;Possible Hilar Lymph Node Involvement;17
5.6.3;Vascular Invasion;18
5.6.4;Liver Volumetry;19
5.6.5;Presence of Extrahepatic Disease;19
5.7;Follow-Up for Recurrent Metastatic Disease;20
5.7.1;Follow-Up of Patients After Surgical Resection of CRC Hepatic Metastases;20
5.7.2;Imaging and Follow-Up After Radiofrequency Ablation;20
5.8;References;22
6;Biology of Colorectal Cancer Liver Metastases;24
6.1;Colorectal Hepatic Metastases Formation;24
6.2;Alteration of Cell-Cell and Cell-Matrix Interactions;24
6.2.1;Epithelial to Mesenchymal Transition;24
6.3;Invasion and Metastasis;27
6.3.1;Src in CRC Metastasis;27
6.4;Migration and Motility;27
6.5;Growth factors and Tumor Angiogenesis;28
6.5.1;Vascular Endothelial Growth Factor;28
6.6;Liver Metastases and Apoptosis;29
6.7;Anti-Angiogenic Treatment of Liver Metastases;29
6.7.1;Anti-VEGF Therapy;29
6.7.2;Inhibitors of Epidermal Growth factor;30
6.8;Summary;31
6.9;References;31
7;Surgery for Colorectal Metastases;34
7.1;Introduction;34
7.2;Selection of Patients for Hepatic Resection;34
7.2.1;Patients General Medical Fitness;34
7.2.2;Assessment of Tumor Resectability and Anticipated Extent of Resection;34
7.3;Definition of Resectability-A Changing Paradigm;35
7.3.1;Multinodular and/or Bilateral Disease;35
7.3.2;Size >5 cm;35
7.3.3;Surgical Margin;35
7.3.4;Hepatic and Pulmonary Metastases;35
7.3.5;Other Sites of Extrahepatic Disease;36
7.3.6;Prognostic Factors;36
7.4;Ensuring Sufficient Functional Hepatic Reserve and Strategies to Increase Resectability;37
7.4.1;Measuring the Future Liver Remnant (FLR);37
7.4.1.1;Portal Vein Embolization (PVE);37
7.4.1.2;Two-Stage Hepatectomy;37
7.4.1.3;Repeat Hepatectomy;38
7.5;Anesthesia and Operative Considerations;38
7.5.1;Anesthesia;38
7.5.2;Methods for Parenchymal Transection;39
7.5.3;Intraoperative Ultrasound (IOUS);40
7.5.4;Anatomic Versus Wedge Resection;40
7.5.5;Evolving Role of Laparoscopic Hepatectomy;40
7.6;Surgery in the Era of Multimodality Therapy;41
7.6.1;Systemic Chemotherapy for Initially Irresectable Disease;41
7.6.2;Systemic Chemotherapy for Initially Resectable Disease;41
7.6.3;Chemotherapy-Induced Liver Injury;41
7.6.4;Biologic Agents;43
7.7;Management of Synchronous Colorectal Liver Metastases;44
7.8;Conclusions;44
7.9;References;45
8;Destructive Therapies for Colorectal Cancer Metastases;48
8.1;Introduction;48
8.2;Cryoablation;48
8.3;Radiofrequency Ablation;49
8.4;Microwave Coagulation Therapy;54
8.5;Other Ablation Therapies;55
8.5.1;Percutaneous Ethanol Injection (PEI);55
8.6;Interstitial Laser Photocoagulation;55
8.6.1;High-Intensity Focused Ultrasound;55
8.6.2;Radiation Therapy;56
8.7;Conclusions;56
8.8;References;57
9;Systemic Therapy for Non-operable Colorectal Cancer Metastases;59
9.1;Systemic Treatment Strategies;59
9.1.1;Chemotherapeutic Agents;59
9.1.1.1;5-Fluorouracil;59
9.1.1.2;Capecitabine;60
9.1.1.3;Irinotecan;61
9.1.1.4;Oxaliplatin;61
9.1.2;Monoclonal Antibodies;62
9.1.2.1;Bevacizumab;62
9.1.2.2;Cetuximab*;63
9.1.2.3;Panitumumab*;63
9.1.3;Recommendations for Systemic Treatments;64
9.2;Localized Treatment Strategies;64
9.2.1;Hepatic Artery Infusion;64
9.2.2;Neoadjuvant Chemotherapy;65
9.3;Conclusion;65
9.4;References;65
10;Locoregional Chemotherapy for Hepatic Metastasis of Colorectal Cancer;67
10.1;Introduction;67
10.2;Placement Technique;67
10.3;Historical Perspective;69
10.4;Randomized Clinical Trials;69
10.4.1;Primary Therapy;69
10.4.2;Secondary Therapy;70
10.4.3;Adjuvant Therapy Postresection;71
10.4.4;Ablative Techniques;71
10.4.5;Newer Agents Via HAI;72
10.5;Summary;73
10.6;References;74
11;Oncosurgical Strategies for Unresectable Liver Metastases;76
11.1;Introduction;76
11.2; Definition of Unresectability;76
11.3;Improving Resectability;77
11.3.1;Downstaging with Preoperative Chemotherapy;77
11.3.1.1;Conversion to Resectability;77
11.3.1.2;Chemotherapy Combined with Biological Agents;78
11.3.1.3;Risks Related to Preoperative Chemotherapy;78
11.3.2;Increasing Resectability with Specific Techniques;79
11.3.2.1;Portal Vein Embolization (PVE);79
11.3.2.2;Local Treatment Modalities;80
11.3.2.3;Two-Stage Hepatectomy;80
11.3.2.4;Extreme Liver Resections;81
11.4;Treatment Strategies;81
11.5;Summary;81
11.6;Case Report: Hepatic Resection Combined with Local Treatment;82
11.7;Case Report: Two-Stage Hepatectomy and Portal Vein Embolization;82
11.8;Case Report: Two-Stage Hepatectomy, Portal Vein Embolization, and Radiofrequency Ablation;84
11.9;References;87
12;Adjuvant Chemotherapy;89
12.1;Introduction;89
12.2;Adjuvant Chemotherapy;89
12.2.1;Hepatic Arterial Infusion of Chemotherapy with or Without Systemic Chemotherapy After Resection of Hepatic Metastases;89
12.2.2;Systemic Chemotherapy After Resection of Hepatic Metastases;90
12.3;Neoadjuvant Chemotherapy;91
12.3.1;The Rationale for Neoadjuvant Chemotherapy in Patients with Resectable Liver Metastases;91
12.3.2;The Potential Drawbacks of Neoadjuvant Chemotherapy;92
12.3.2.1;Complete Response Before Surgery;92
12.3.2.2;Chemotherapy-Associated Hepatotoxicity;92
12.3.3;Results of Neoadjuvant Chemotherapy in Patients with Resectable Liver Metastases;93
12.4;Neoadjuvant Therapies Including Targeted Agents;94
12.5;Conclusions;94
12.6;References;94
13;Biologicals for Colorectal Cancer Metastases;96
13.1;EGFR-Targeted Therapy;96
13.1.1;EGFR Antibodies in Pretreated Patients with Metastatic Colorectal Cancer;96
13.1.2;Toxicity of EGFR Antibodies;97
13.1.3;Preclinical Markers for Efficacy;97
13.1.4;EGFR Antibodies in Untreated Patients;97
13.1.5;EGFR Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer;97
13.2;Anti-Angiogenetic Therapy;99
13.2.1;VEGF Antibody;99
13.2.2;VEGFR and Multiple Tyrosine Kinase Inhibitors;100
13.3;References;100
14;Internal Radiation for the Treatment of Liver Metastases;103
14.1;Introduction;103
14.2;Radioactive Material;104
14.3;Radiation Treatment Planning;104
14.3.1;Empiric Method;105
14.4;Dose Delivery;106
14.5;Laboratory Studies;106
14.6;Imaging Studies;106
14.7;Hepatic Angiography;106
14.8;Nuclear Medicine Studies;107
14.9;Toxicity;107
14.10;Patient Selection;107
14.11;Colorectal Cancer Metastases;108
14.12;Breast Cancer Metastases;109
14.13;Neuroendocrine Tumor Metastases;109
14.14;Discussion;109
14.15;References;111
15;Surgical Treatment of Colorectal Liver Metastases in Elderly Patients;114
15.1;Epidemiology Of Aging And Colorectal Cancer In The Western World;114
15.2;Physiological Changes In The Aging Liver;115
15.3;Comorbidity;115
15.4;Techniques In Hepatic Resection;116
15.5;Outcome;116
15.6;Summary;118
15.7;References;118
16;Health-Related Quality of Life and Palliative Care in Colorectal Liver Metastases;120
16.1;Background;120
16.2;What Is Health-Related Quality of Life?;121
16.3;Measurements of Health-Related Quality of Life;121
16.3.1;The Modular Approach to HRQoL Measures;121
16.3.1.1;The European Organisation for Research and Treatment of Cancer (EORTC) Core QL Questionnaire (QLQ-C30);122
16.3.1.2;The Functional Assessment of Cancer Therapy-General (FACT-G);122
16.3.2;Development of a Questionnaire Module Specific to Patients with Colorectal Liver Metastases;122
16.4;Methodological Issues in HRQoL: Implications for Advanced Colorectal Cancer Clinical Trials;122
16.4.1;Lack of A Priori Hypothesis About Possible QoL Changes Before Commencing The Trial;123
16.4.2;Rationale for Selecting a Specific Measure;123
16.4.3;Baseline Data and Missing Data;123
16.4.4;Timing;123
16.4.5;Data Analysis and Interpretation;123
16.4.6;Reporting Results;123
16.5;Psychological Distress;124
16.6;Anxiety;125
16.7;Depression;125
16.7.1;Screening for Depression;126
16.7.2;Hospital Anxiety and Depression Scale (HADS);126
16.7.3;Edinburgh Depression Scale (EDS);126
16.8;Social Functioning and Quality of Life;127
16.9;Spiritual Aspects of Quality of Life;127
16.10;Predictive Value of Qol Parameters: The Emergence of Social Functioning;127
16.11;Liver Metastases and Palliative Care: Advanced Stages;128
16.11.1;Pain;128
16.11.2;Jaundice;128
16.11.3;Nausea;128
16.11.4;Pruritus;129
16.11.5;Poor Appetite;129
16.11.6;Confusion and the Terminal Phase;129
16.12;Caregivers and Palliative Care in Liver Metastases;129
16.13;Summary;130
16.14;References;130
17;Carcinoid Liver Metastases: The Carcinoid Syndrome;132
17.1;Introduction;132
17.2;Detecting Metastatic Carcinoid Disease;132
17.3;Treatment of Carcinoid Liver Metastases;133
17.3.1;Resection;133
17.3.2;Chemoembolisation;134
17.3.3;Somatostatin Analogues;134
17.3.4;Targeted Nuclear Treatments;135
17.3.5;Systemic Therapies;136
17.4;Quality of Life;136
17.5;References;136
18;Gastrointestinal Stromal Tumors;140
18.1;Introduction;140
18.2;Pathology;140
18.2.1;Light Microscopy and Immunohistochemistry;140
18.2.2;Molecular Pathology;141
18.2.3;Epidemiology;141
18.2.4;Organ Specific Studies;142
18.3;Clinical Disease;142
18.3.1;Diagnosis;142
18.3.1.1;Imaging;142
18.3.1.2;Biopsy;143
18.3.1.3;Endoscopic Ultrasound;143
18.4;Treatment;143
18.4.1;Surgery;143
18.4.1.1;Risk of Recurrence;144
18.4.1.2;Laparoscopy;144
18.4.2;Cytotoxic Chemotherapy;144
18.4.3;Imatinib Mesylate;144
18.4.3.1;Imatinib for the Treatment of Locally Advanced and Metastatic GIST;145
18.4.3.2;Mutational Assessment and Use of Imatinib;145
18.5;Results from Escalating Doses of Imatinib;146
18.5.1; ;146
18.5.1.1;Duration of Therapy;146
18.5.2;Surgery Plus Imatinib;146
18.5.2.1;Neoadjuvant Imatinib or Surgery;146
18.5.3;Assessing Response to Imatinib;147
18.5.4;Sunitinib Malate;147
18.5.5;Mechanisms of Drug Resistance;147
18.5.6;Additional Systemic Agents;148
18.5.7;Hepatic Arterial Chemoembolization;148
18.6;Conclusions;149
18.7;References;149
19;Surgery for Breast Cancer Liver Metastases;152
19.1;Introduction;152
19.2;Metastatic Disease;152
19.3;Patient Selection;153
19.4;Liver Resection Of Breast Cancer Metastases;154
19.5;Liver Ablation Of Breast Cancer Metastases;155
19.6;Conclusion;156
19.7;References;156
20;Liver-Directed Therapy for Metastatic Melanoma to the Liver;158
20.1;Introduction;158
20.2;Melanoma: Primary Tumor Site;158
20.2.1;Ocular;158
20.2.2;Cutaneous;159
20.3;Therapeutic Options for Melanoma Hepatic Metastases;160
20.3.1;Systemic Chemotherapy;160
20.3.2;Locoregional Therapies;161
20.3.2.1;Hepatic Artery Infusion Therapy;161
20.3.2.2;Transarterial Hepatic Artery Chemoembolization;163
20.3.2.3;Isolated Hepatic Perfusion;164
20.3.3;Surgical Resection;166
20.4;Conclusion;168
20.5;References;169
21;Non-colorectal Gastrointestinal Liver Metastases;172
21.1;Introduction;172
21.2;Esophageal and Gastroesophageal Junction Cancer;173
21.2.1;Background and Epidemiology;173
21.2.2;Presentation and Diagnosis;173
21.2.3;Role of Surgery;174
21.2.4;Role of Adjuvant Therapies;174
21.2.5;Recent Novel Approaches;174
21.3;Gastric Cancer;175
21.3.1;Background and Epidemiology;175
21.3.2;Presentation and Diagnosis;175
21.3.3;Role of Surgery;175
21.3.4;Role of Adjuvant Therapies;175
21.3.5;Recent Novel Approaches;176
21.4;Duodenal and Small Bowel Cancer;176
21.4.1;Background and Epidemiology;176
21.4.2;Presentation and Diagnosis;176
21.4.3;Role Of Surgery;176
21.4.4;Role of Adjuvant Therapies;177
21.4.5;Recent Novel Approaches;177
21.5;Biliary Cancers;177
21.5.1;Background And Epidemiology;177
21.5.2;Presentation and Diagnosis;177
21.5.3;Role of Surgery;178
21.5.4;Role of Adjuvant Therapies;178
21.5.5;Recent Novel Approaches;178
21.6;Pancreatic Cancer;178
21.6.1;Background and Epidemiology;178
21.7;Presentation and Diagnosis;179
21.7.1;Role of Surgery;179
21.7.2;Role of Adjuvant Therapies;179
21.7.3;Recent Novel Approaches;179
21.8;Conclusion;179
21.9;References;180
22;Index;182mehr

Autor